FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235.

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							50	(··/ o. til			pa, , tot							
1. Name and Address of Reporting Person* HOBBS EAMONN P						2. Issuer Name and Ticker or Trading Symbol ANGIODYNAMICS INC [ANGO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 603 QUEENSBURY AVE.						3. Date of Earliest Transaction (Month/Day/Year) 11/01/2005 X Officer (give title below) President & CEO											specify	
(Street) QUEENSBURY NY 12804						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)						- 6-		A		1 D:		f D						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/					action	ion 2A. Deemed Execution Date,			3. 4. Securities Transaction Disposed O Code (Instr.		es Acquired (A) or Of (D) (Instr. 3, 4 and 5		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		orted nsaction(s) tr. 3 and 4)			(Instr. 4)
Common Stock 11/01/2								M ⁽¹⁾		7,500	A	\$4.347		/		D		
Common Stock 11/01/20						ive Securities Acc				Dia	7,500	D D	\$21.50		,789		D	
			таріе іі								convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any			ransaction Code (Instr.		ivative urities juired or posed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Derivative derivative Security Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to buy)	\$4.3478	11/01/2005			M ⁽¹⁾			7,500	12/30/20	004	03/04/2007	Common Stock	7,500	\$0	273,182		D	
Non- Qualified Stock Option (right to buy)	\$4.3478								12/30/20	004	05/30/2008	Common Stock	2,091		2,091		D	
Non- Qualified Stock Option (right to buy)	\$4.3478								12/30/20	004	05/29/2009	Common Stock	2,091		2,091		D	
Non- Qualified Stock Option (right to buy)	\$4.3478								06/03/20	05 ⁽²⁾	06/03/2010	Common Stock	2,091		2,091		D	
Non- Qualified Stock Option (right to buy)	\$4.3478								06/02/20	05 ⁽³⁾	06/02/2011	Common Stock	2,091		2,091		D	
Non- Qualified Stock Option (right to buy)	\$13.18								07/20/20	05 ⁽⁴⁾	07/20/2014	Common Stock	35,500		35,500	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$24.21							07/29/2006 ⁽⁵⁾	07/29/2015	Common Stock	45,000		45,000	D	
Restricted Stock Units	\$0 ⁽⁶⁾							05/30/2009	05/29/2019	Common Stock	8,250		8,250	D	

Explanation of Responses:

- $1.\ Transaction\ executed\ pursuant\ to\ an\ approved\ selling\ plan\ established\ under\ SEC\ rule\ 10b5-1.$
- $2. \ Options \ for \ 80\% \ of \ the \ shares \ are \ exercisable \ on \ 12/30/04. \ Options \ for \ 20\% \ of \ the \ shares \ are \ exercisable \ on \ 6/3/2005.$
- 3. Options for 60% of the shares are exercisable on 12/30/2004. Options for 20% of the shares are exercisable on 6/2/2005. Options for 20% of the shares will become exercisable on 6/2/2006.
- $4. \ Options \ for \ 25\% \ of \ the \ shares \ are \ each \ exercisable \ on \ 7/20/05, \ 7/20/06, \ 7/20/08, \ respectively.$
- 5. Options for 25% of the shares are each exercisable on 7/29/06, 7/29/07, 7/29/08, and 7/29/09, respectively.
- 6. Each restricted stock unit represents a contingent right to receive one share of AngioDynamics, Inc. common stock.

By: Ronald F. Lamy For: 11/02/2005 Eamonn P. Hobbs

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Joseph G. Gerardi and Ronald F. Lamy, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of AngioDynamics, Inc., Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of May 2004.

/s/ Eamonn P. Hobbs _